Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. Mylan applies one global quality standard across our facilities, and across our product line regardless of market. At Mylan, whether it’s a medication for millions or for a handful of people our priorities are to meet or exceed industry standards.

Company Growth (employees)
Type
Public
HQ
Canonsburg, US
Founded
1961
Size (employees)
35,000 (est)
Website
mylan.com
Mylan was founded in 1961 and is headquartered in Canonsburg, US

Key People/Management at Mylan

Heather Bresch

Heather Bresch

Chief Executive Officer

Mylan Office Locations

Mylan has an office in Canonsburg
Canonsburg, US (HQ)
1000 Mylan Boulevard

Mylan Financials and Metrics

Mylan Financials

Mylan's revenue was reported to be $7.6 b in FY, 2014 which is a 12% increase from the previous period.
USD

Revenue (FY, 2014)

7.6 b

Revenue growth (FY, 2013 - FY, 2014), %

12%

Gross profit (FY, 2014)

3.5 b

Gross profit margin (FY, 2014), %

45%

Net income (FY, 2014)

933.1 m

Market capitalization (08-Dec-2017)

20.8 b

Cash (31-May-2016)

28.7 k
Mylan's current market capitalization is $20.8 b.
USDFY, 2013FY, 2014

Revenue

6.9 b7.6 b

Revenue growth, %

12%

Cost of goods sold

3.9 b4.2 b

Gross profit

3 b3.5 b
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

2.5 k5.9 k1.8 k163325.1 k5.2 k28.9 k15.3 k28.7 k

Accounts Receivable

9753722.5 k17.4 k5.4 k5 k9.3 k20 k12.7 k

Inventories

1.7 b1.7 b

Current Assets

3.4 k5.9 k2.2 k2.6 k17.4 k10.5 k10.2 k38.1 k35.3 k41.4 k
    USDFY, 2013FY, 2014

    Net Income

    626.5 m933.1 m

    Depreciation and Amortization

    516 m566.6 m

    Accounts Receivable

    (550 m)(940 m)

    Inventories

    (160 m)(150 m)
    Y, 2016

    Financial Leverage

    484.1 x
    Show all financial metrics

    Mylan Market Value History

    Mylan Median Salaries

    Source: 123 public H-1B filings from Mylan

    Mylan's Web-traffic and Trends

    Mylan Online and Social Media Presence

    Mylan News and Updates

    Future Growth of Retropharyngeal Abscess Market with expected to reach 4.5% CAGR by 2023

    Market Research Future has a half cooked research report on the global retropharyngeal abscess market, The Retropharyngeal Abscess Market Growth at a CAGR of ~ 4.5 % Over The Forecast Period 2017-2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

    Concordia catches antitrust scrutiny over 5,700% price rise for thyroid drug

    Antitrust watchdogs are targeting Concordia Healthcare and its pricing for liothyonine, a thyroid drug they say is 57 times more expensive now than it was in 2006. The U.K. generics pricing probe is the latest to surface since authorities there levied a record $108 million fine against Pfizer last y…

    Biocon and Mylan say their plant is good to go as FDA decision nears for their Herceptin copy

    Biocon has resolved FDA concerns about a biologics plant in India, a step that sets it and partner Mylan up to potentially win the first U.S. approval of a biosimilar of Roche’s blockbuster cancer drug Herceptin.

    Mylan's EpiPen sales plummet as pricing scandal bites back

    For evidence that a pricing scandal can translate into real lost sales for a pharmaceutical company, look no further than Mylan's third-quarter results. The now-infamous EpiPen took a $245 million hit to sales, partly on higher rebates required by a Justice Department settlement.

    Teva cuts guidance yet again as Copaxone copies, generics pressure take their toll

    On a day that Teva chairman Sol Barer described as “the beginning of the next chapter for our company,” all analysts got was more of the same. For the third time in the last four quarters, the company slashed its guidance, bringing its expected revenue range down to $22.2 billion to $22.3 billion.

    World Varicocele Treatment Market is Expected to Reach 617.5 Million By 2023

    Market research future has a half cooked research report on global varicocele treatment market. The global varicocele treatment market is growing continuously and expected to grow at a CAGR of 6.2% from 2017 to 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday
    Show more

    Mylan Company Life and Culture

    You may also be interested in